- Conditions
- Acute Pain
- Interventions
- Arginine vasopressin, Saline, Observational learning, fMRI data aquisition
- Drug · Other · Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–643
of 643
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- fluorine F 18 fluorothymidine, positron emission tomography
- Other · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ischemia, Stress, Mental
- Interventions
- Coronary CT Angiography, Mood Symptom Scale, Anxiety Symptom Scale, Chronic Stress Inventories, Psychosocial Function Questionnaires, General Health and quality of life questionnaires, Magnetic Resonance Imaging
- Radiation · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy
- Radiation · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 56
- States / cities
- Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more
- Conditions
- Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
- Interventions
- MRF in conjunction with IVIM MRI without contrast
- Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Healthy Adult Participants, Healthy Participants
- Interventions
- Magnetic Resonance Imaging (MRI), Broad thalamic stimulation (TI-TES), Carrier only SHAM stimulation, Anterior thalamic stimulation (TI-TES), Posterior thalamic stimulation (TI-TES)
- Other · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Epilepsy
- Interventions
- EEG, Eye Tracking, Behavioral task, fMRI
- Device · Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Kansas City, Kansas • Boston, Massachusetts + 5 more
- Conditions
- Healthy
- Interventions
- Functional Magnetic Resonance Imaging (fMRI)
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Glioblastoma
- Interventions
- Avastin, Lomustine, Temozolomide, MRI, MRS, DSC
- Radiation · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
- Interventions
- MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
- Interventions
- Brain Magnetic Resonance Imaging (MRI), Whole Genome Sequencing, Induced Pluripotential Stem Cells
- Diagnostic Test · Genetic · Other
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 0 Years to 99 Years
- Enrollment
- 50 participants
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Gender Dysphoria
- Interventions
- Magnetic Resonance Imaging, Cognition and Health Tests, Optional Exercise Test
- Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Menopause, Depression
- Interventions
- MDD diagnosis and Estrogen treatment, MDD diagnosis and Fluoxetine treatment, MDD diagnosis with both Estrogen and Fluoxetine treatment, No depression and estrogen treatment
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Menopause, Brain Activity, Cognition
- Interventions
- Lisdexamfetamine, Placebo
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 479
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
- Conditions
- Brain Metastases
- Interventions
- Stereotactic Radiosurgery, Surgical Resection, Magnetic Resonance Imaging
- Device · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Single Ventricle Defect
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Months to 10 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging, Optical Coherence Tomography
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 27
- States / cities
- Aurora, Colorado • Coral Gables, Florida • Deerfield Beach, Florida + 19 more
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 138
- States / cities
- Anchorage, Alaska • Bakersfield, California • Irvine, California + 114 more